Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 16;114(4):362-7.
doi: 10.1038/bjc.2015.435. Epub 2016 Jan 7.

Antibody-drug conjugates--an emerging class of cancer treatment

Nikolaos Diamantis  1 , Udai Banerji  1
Affiliations
Review

Antibody-drug conjugates--an emerging class of cancer treatment

Nikolaos Diamantis et al. Br J Cancer. .

Abstract

Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent cytotoxic payloads has permitted the development of more effective and safe ADCs. In recent years, two ADCs have been licensed, T-DM1 and brentuximab vedotin, and are already establishing their place in cancer treatment. A plethora of ADCs are being investigated in phases I and II trials, emerging data of which appears promising. As we deepen our understanding of what makes a successful ADC, an increasing number of ADCs will likely become viable treatment options as single agents or in combination with chemotherapy. This review will present the philosophy underlying ADCs, their main characteristics and current research developments with a focus on ADCs in solid tumours.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Target antigens for ADCs in solid tumours.
See this image and copyright information in PMC

References

    1. Agarwal P, Bertozzi CR (2015) Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem 26(2): 176–192. - PMC - PubMed
    1. Barok M, Joensuu H, Isola J (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 16(2): 209. - PMC - PubMed
    1. Baselga J, Verma S, Ro J, Huober J, Guardino E, Fang L, Olsen S, Phillips GL, de Haas S, Pegram M (2013) Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. AACR Annual Meeting. Abstract LB-63 Presented April 7, 2013. - PubMed
    1. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM (2011) SAR3419: an anti-CD19-Maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 17(20): 6448–6458. - PubMed
    1. Boghaert ER, Khandke KM, Sridharan L, Dougher M, DiJoseph JF, Kunz A, Hamann PR, Moran J, Chaudhary I, Damle NK (2008) Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother Pharmacol 61(6): 1027–1035. - PubMed

Publication types

MeSH terms